Latest Insider Transactions at Vaxart, Inc. (VXRT)
This section provides a real-time view of insider transactions for Vaxart, Inc. (VXRT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vaxart, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vaxart, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
W. Mark Watson Director |
BUY
Open market or private purchase
|
Direct |
20,000
+20.38%
|
$0
$0.68 P/Share
|
|
Jun 12
2024
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,007
-0.83%
|
$0
$0.76 P/Share
|
|
Jun 11
2024
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+28.29%
|
-
|
|
Jun 11
2024
|
Michael J. Finney Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+2.28%
|
-
|
|
Jun 11
2024
|
David E. Wheadon Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+34.22%
|
-
|
|
Jun 11
2024
|
Robert A. Yedid Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+31.69%
|
-
|
|
Jun 11
2024
|
W. Mark Watson Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+21.59%
|
-
|
|
Mar 28
2024
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,902
-1.09%
|
$3,902
$1.3 P/Share
|
|
Mar 28
2024
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,292
-1.0%
|
$3,292
$1.3 P/Share
|
|
Mar 18
2024
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+27.12%
|
-
|
|
Mar 18
2024
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+17.64%
|
-
|
|
Mar 18
2024
|
Edward B Berg SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+24.95%
|
-
|
|
Mar 18
2024
|
James F. Cummings Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+21.42%
|
-
|
|
Mar 18
2024
|
Steven Lo President, Chief Exec Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
|
Feb 02
2024
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,220
-2.72%
|
$9,220
$1.2 P/Share
|
|
Feb 02
2024
|
Edward B Berg SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,220
-4.85%
|
$9,220
$1.2 P/Share
|
|
Feb 02
2024
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,965
-3.21%
|
$7,965
$1.2 P/Share
|
|
Dec 15
2023
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,943
-3.77%
|
$0
$0.63 P/Share
|
|
Dec 08
2023
|
Phillip E Lee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
35,151
-18.22%
|
$0
$0.71 P/Share
|
|
Dec 08
2023
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,288
-9.18%
|
$0
$0.71 P/Share
|
|
Dec 08
2023
|
Edward B Berg SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
33,752
-15.09%
|
$0
$0.71 P/Share
|
|
Dec 08
2023
|
James F. Cummings Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31,409
-11.24%
|
$0
$0.71 P/Share
|
|
Jun 26
2023
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,922
+21.98%
|
-
|
|
Jun 26
2023
|
W. Mark Watson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+14.9%
|
-
|
|
Jun 26
2023
|
David E. Wheadon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+33.33%
|
-
|
|
Jun 26
2023
|
Robert A. Yedid Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+28.51%
|
-
|
|
Jun 26
2023
|
Michael J. Finney Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+1.09%
|
-
|
|
Jun 12
2023
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+10.45%
|
-
|
|
Mar 28
2023
|
Sean Tucker SVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,683
-0.98%
|
$0
$0.75 P/Share
|
|
Mar 17
2023
|
Edward B Berg SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
187,606
+39.15%
|
-
|
|
Mar 17
2023
|
Cezar Andrei Floroiu President, Chief Exec Officer |
BUY
Grant, award, or other acquisition
|
Direct |
367,735
+29.33%
|
-
|
|
Mar 17
2023
|
James F. Cummings Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,350
+29.89%
|
-
|
|
Mar 17
2023
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
189,157
+20.69%
|
-
|
|
Mar 17
2023
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
191,652
+26.33%
|
-
|
|
Dec 28
2022
|
W. Mark Watson Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$0
$0.76 P/Share
|
|
Dec 16
2022
|
Phillip E Lee Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+50.0%
|
-
|
|
Aug 25
2022
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,750
+45.53%
|
-
|
|
Aug 24
2022
|
Robert A. Yedid Director |
SELL
Bona fide gift
|
Direct |
26,240
-32.07%
|
-
|
|
Aug 19
2022
|
Robert A. Yedid Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,240
+27.98%
|
$26,240
$1.35 P/Share
|
|
Aug 04
2022
|
W. Mark Watson Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,750
+50.0%
|
-
|
|
Aug 04
2022
|
Robert A. Yedid Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+39.89%
|
-
|
|
Aug 04
2022
|
David E. Wheadon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+50.0%
|
-
|
|
Aug 04
2022
|
Michael J. Finney Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+1.1%
|
-
|
|
Aug 04
2022
|
Todd C Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,375
+5.53%
|
-
|
|
Aug 04
2022
|
Julie M Cherrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,217
+50.0%
|
-
|
|
Jun 22
2022
|
Fuad Ahmad Interim CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$15,000
$3.22 P/Share
|
|
Apr 22
2022
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+23.86%
|
$0
$0.77 P/Share
|
|
Mar 28
2022
|
Sean Tucker SVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+33.3%
|
-
|
|
Mar 28
2022
|
Cezar Andrei Floroiu President, Chief Exec Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Mar 28
2022
|
James F. Cummings Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+50.0%
|
-
|